DC Circ. Backs FDA's Approval Of Abilify Maintena Rival
The U.S. Food and Drug Administration acted reasonably when it approved a near-copy of Otsuka Pharmaceutical's antipsychotic Abilify Maintena despite unexpired exclusivity for Otsuka's product, the D.C. Circuit ruled Tuesday....To view the full article, register now.
Already a subscriber? Click here to view full article